Colleen Kusy
Stock Analyst at Baird
(0.94)
# 3,672
Out of 4,761 analysts
40
Total ratings
25%
Success rate
-10.59%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Colleen Kusy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CHRS Coherus BioSciences | Maintains: Outperform | $4 → $6 | $1.07 | +460.75% | 5 | Dec 5, 2024 | |
| ELVN Enliven Therapeutics | Maintains: Outperform | $32 → $40 | $21.80 | +83.49% | 2 | Nov 15, 2024 | |
| SYRE Spyre Therapeutics | Maintains: Outperform | $50 → $65 | $21.29 | +205.31% | 2 | Nov 13, 2024 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $92 → $55 | $27.52 | +99.85% | 10 | Nov 7, 2024 | |
| MRSN Mersana Therapeutics | Maintains: Neutral | $4 → $3 | $0.53 | +462.64% | 4 | Aug 14, 2024 | |
| OCUL Ocular Therapeutix | Maintains: Outperform | $18 → $17 | $7.00 | +142.86% | 4 | Aug 8, 2024 | |
| OCS Oculis Holding AG | Maintains: Outperform | $35 → $37 | $21.41 | +72.82% | 3 | Jun 11, 2024 | |
| ORIC ORIC Pharmaceuticals | Reiterates: Outperform | $27 → $25 | $7.68 | +225.52% | 1 | Mar 12, 2024 | |
| NUVL Nuvalent | Initiates: Outperform | $105 | $79.49 | +32.09% | 1 | Feb 23, 2024 | |
| AGEN Agenus | Initiates: Outperform | $160 | $3.32 | +4,719.28% | 1 | Jun 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $14 | $0.60 | +2,239.57% | 1 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $5.78 | +488.24% | 5 | Apr 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $230 | $1.82 | +12,537.36% | 1 | Nov 2, 2021 |
Coherus BioSciences
Dec 5, 2024
Maintains: Outperform
Price Target: $4 → $6
Current: $1.07
Upside: +460.75%
Enliven Therapeutics
Nov 15, 2024
Maintains: Outperform
Price Target: $32 → $40
Current: $21.80
Upside: +83.49%
Spyre Therapeutics
Nov 13, 2024
Maintains: Outperform
Price Target: $50 → $65
Current: $21.29
Upside: +205.31%
Apellis Pharmaceuticals
Nov 7, 2024
Maintains: Outperform
Price Target: $92 → $55
Current: $27.52
Upside: +99.85%
Mersana Therapeutics
Aug 14, 2024
Maintains: Neutral
Price Target: $4 → $3
Current: $0.53
Upside: +462.64%
Ocular Therapeutix
Aug 8, 2024
Maintains: Outperform
Price Target: $18 → $17
Current: $7.00
Upside: +142.86%
Oculis Holding AG
Jun 11, 2024
Maintains: Outperform
Price Target: $35 → $37
Current: $21.41
Upside: +72.82%
ORIC Pharmaceuticals
Mar 12, 2024
Reiterates: Outperform
Price Target: $27 → $25
Current: $7.68
Upside: +225.52%
Nuvalent
Feb 23, 2024
Initiates: Outperform
Price Target: $105
Current: $79.49
Upside: +32.09%
Agenus
Jun 6, 2023
Initiates: Outperform
Price Target: $160
Current: $3.32
Upside: +4,719.28%
Aug 5, 2022
Maintains: Outperform
Price Target: $17 → $14
Current: $0.60
Upside: +2,239.57%
Apr 7, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $5.78
Upside: +488.24%
Nov 2, 2021
Initiates: Outperform
Price Target: $230
Current: $1.82
Upside: +12,537.36%